FDA Grants U.K. Firm Incentives to Develop Cannabis-Based Drug
U.S. regulators granted GW Pharmaceuticals’ cannabis-based epilepsy drug “orphan” status, enabling the company to receive tax credits and…
News April 25
Latest In: FDA
Study Results Send GW Pharma’s Stock Soaring
A British maker of cannabis-based drugs revealed some sorely needed good news on Monday, announcing that an epilepsy medicine…
News March 14
Ripple Effects of the FDA’s Stance on CBD Products: Q&A With Attorney Robert Hoban
By John Schroyer When the U.S. Food and Drug Administration stepped in – again – to warn CBD…
News February 24FDA Warns Eight CBD Producers to Quit Making Medical Claims
A year ago, the U.S. Food and Drug Administration warned six companies to stop making claims about the…
News February 11
FDA Says CBD Products Don’t Qualify as Dietary Supplements
The U.S. Food and Drug Administration has ruled that cannabidiol products don’t fit under the legal definition of…
News May 15
FDA Warnings Could Signal Start of Heavier Scrutiny on Cannabis Industry
In late February, the U.S. Food and Drug Administration sent stern letters to six companies peddling CBD products…
News March 10Featured
1
Latest Sponsored
